CARL CARLSMED, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1794546 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY60.4%
TTM net income YoY-55.6%
TTM EPS YoY65.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin77.0%
Operating margin-59.0%
Net margin-55.8%
FCF margin-48.6%
EBITDA margin-58.4%
Returns
ROE-43.9%
ROA-32.0%
ROIC (approx.)-108.1%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets34.4%
Debt / equity0.20x
Current ratio5.79x
Interest coverage-33.33x
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $21.55M | $18.94M | $16.12M | $15.16M | $13.07M | $12.08M | $10.19M | $9.41M |
| Cost of revenue | $4.89M | $4.40M | $3.69M | $3.56M | $3.15M | $3.21M | $2.55M | $2.38M |
| Gross profit | $16.66M | $14.54M | $12.43M | $11.61M | $9.93M | $8.87M | $7.64M | $7.02M |
| R&D expense | $6.38M | $6.04M | $5.18M | $5.26M | $4.45M | $4.16M | $3.15M | $3.02M |
| SG&A expense | $9.98M | $7.62M | $6.23M | $4.85M | $4.91M | $3.34M | $3.47M | $2.33M |
| Operating income | -$12.70M | -$11.04M | -$9.28M | -$9.32M | -$9.04M | -$6.50M | -$5.72M | -$4.70M |
| Interest expense | $316,000 | $313,000 | $311,000 | $330,000 | $380,000 | $363,000 | $357,000 | $378,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.24M | -$10.51M | -$8.70M | -$8.61M | -$8.53M | -$6.77M | -$5.73M | -$4.72M |
| EBITDA | -$12.60M | -$10.94M | -$9.18M | -$9.22M | -$8.94M | -$6.40M | -$5.68M | -$4.66M |
| EPS (basic) | -0.45 | -0.39 | -0.32 | — | -0.40 | -1.47 | -1.47 | — |
| EPS (diluted) | -0.45 | -0.39 | -0.32 | — | -0.40 | -1.47 | -1.47 | — |
| Weighted avg. shares (diluted) | 27.30M | 27.19M | 26.84M | — | 21.08M | 4.59M | 4.30M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $35.95M | $46.24M | $73.02M | $85.79M | $115.37M | $33.47M | $43.43M | $40.12M |
| Short-term investments | $24.00M | $24.00M | $24.00M | $24.00M | — | — | — | $0 |
| Receivables | $16.88M | $13.78M | $12.27M | $11.36M | $11.30M | $9.71M | — | $6.77M |
| Inventory | $2.99M | $2.27M | $2.06M | $1.84M | $1.34M | $1.07M | — | $995,000 |
| Current assets | $105.56M | $109.60M | $115.41M | $126.67M | $131.47M | $46.19M | — | $49.35M |
| PP&E, net | $3.61M | $2.40M | $1.60M | $1.49M | $1.19M | $972,000 | — | $260,000 |
| Total assets | $115.27M | $118.20M | $118.77M | $130.12M | $134.86M | $53.27M | — | $51.82M |
| Current liabilities | $18.24M | $12.40M | $9.71M | $14.28M | $10.93M | $9.48M | — | $8.82M |
| Long-term debt | $15.40M | $15.38M | $15.36M | $15.35M | $15.44M | $15.43M | — | $15.41M |
| Total debt | $15.40M | $15.38M | $15.36M | $15.35M | $15.44M | $15.43M | — | $15.41M |
| Total liabilities | $39.60M | $33.96M | $26.52M | $31.25M | $28.20M | $27.61M | — | $26.23M |
| Shareholders' equity | $75.67M | $84.25M | $92.25M | $98.87M | $106.66M | -$83.07M | -$76.61M | -$70.63M |
| Net debt | -$20.55M | -$30.86M | -$57.65M | -$70.45M | -$99.93M | -$18.04M | — | -$24.71M |
| Shares outstanding | 27.39M | 27.23M | 27.18M | 26.60M | 26.58M | 4.60M | — | 4.14M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.67M | -$7.36M | -$13.01M | -$5.32M | -$8.46M | -$7.04M | -$8.15M | -$4.20M |
| Capital expenditure | $283,000 | $121,000 | $79,000 | $73,000 | $159,000 | $327,000 | $83,000 | $61,000 |
| Free cash flow | -$8.96M | -$7.48M | -$13.09M | -$5.39M | -$8.62M | -$7.37M | -$8.24M | -$4.26M |
| Investing cash flow | -$1.80M | -$19.66M | -$206,000 | -$24.23M | -$343,000 | -$672,000 | -$238,000 | -$61,000 |
| Financing cash flow | $172,000 | $243,000 | $436,000 | -$29,000 | $90.70M | -$2.25M | $11.70M | -$51,000 |
| Depreciation & amortization | $100,000 | $100,000 | $99,000 | $98,000 | $100,000 | $100,000 | $40,000 | $37,000 |
| Stock-based compensation | $3.28M | $2.27M | $1.63M | $790,000 | $704,000 | $258,000 | $175,000 | $100,000 |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.